Shandong New Time Pharmaceutical Co., Ltd.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
F182112Phase 2Relapsed or Refractory Multiple Myeloma
Est. primary completion 2028-05-20 · NCT07312188 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
F182112Phase 3Relapsed or Refractory Multiple Myeloma (RRMM)
Est. primary completion 2029-01-25 · NCT07579234 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.